Fagron NV (ARSUF) Q2 2026 Earnings Call Transcript
Fagron NV (ARSUF) Q2 2026 Earnings Call July 30, 2026 3:30 AM EDT
Company Participants
Ignacio Artola – Global Head of Investor Relations
Rafael Padilla – CEO & Executive Director
Karin de Jong – CFO & Executive Director
Conference Call Participants
Frank Claassen – Banque Degroof Petercam S.A., Research Division
Stijn Demeester – ING Groep N.V., Research Division
Usama Tariq – ODDO BHF Corporate & Markets, Research Division
Michael Heider – Joh. Berenberg, Gossler & Co. KG, Research Division
Mathijs Geerts Danau – KBC Securities NV, Research Division
Eric Wilmer – Kempen & Co. N.V., Research Division
Presentation
Ignacio Artola
Global Head of Investor Relations
Hello, and good morning, everyone. Welcome to Fagron’s H1 2026 Results Webcast. I’m joined today by our CEO, Rafael Padilla; and our CFO, Karin de Jong. Rafael will start by discussing the company’s performance and a closer look at regional developments. Karin will then walk you through the financial results. We will open the floor for questions at the end of the session.
With that, I will hand over to Rafael.
Rafael Padilla
CEO & Executive Director
Thank you, Ignacio, and good morning all.
We’re pleased to report a strong performance with revenues reaching EUR 552 million. This reflects 3.1% organic growth at CER, 7% when normalizing the GLP-1 effect. Growth was driven by brands, Latin America, B&E North America and EMEA. Profitability grew by 12.7% to EUR 107 million. The margin of 19.4% reflects an improvement in both EMEA and Latin America and temporary effects in North America Pacific compounding services.
On M&A, we closed the acquisition of Amber in Singapore and Malaysia, completing 5 acquisitions across all regions in 2026. We also entered into a collaboration agreement with NutraConnect in Asia, which will complement our nutraceutical platform. Integration of earlier announced acquisition remains on track. We have also appointed Amy Jones to lead the North
